<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00358657</url>
  </required_header>
  <id_info>
    <org_study_id>2032.00</org_study_id>
    <secondary_id>NCI-2010-00192</secondary_id>
    <secondary_id>2032</secondary_id>
    <secondary_id>2032.00</secondary_id>
    <secondary_id>P01HL122173</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG9213024</secondary_id>
    <nct_id>NCT00358657</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders</brief_title>
  <official_title>HLA-Haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning With Low-Dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects of fludarabine phosphate, cyclophosphamide and&#xD;
      total-body irradiation followed by donor bone marrow transplant and cyclophosphamide,&#xD;
      mycophenolate mofetil, tacrolimus, and sirolimus in treating patients with primary&#xD;
      immunodeficiency disorders or noncancerous inherited disorders. Giving low doses of&#xD;
      chemotherapy and total-body irradiation before a bone marrow transplant helps prepare the&#xD;
      patient's body to accept the incoming donor's bone marrow and decrease the risk that the&#xD;
      patient's immune system will reject the donor's stem cells. When the healthy stem cells from&#xD;
      a donor are infused into the patient they may help the patient's bone marrow make stem cells,&#xD;
      red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a&#xD;
      donor can make an immune response against the body's normal cells called graft versus host&#xD;
      disease. Giving cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus after the&#xD;
      transplant may help decrease this from happening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine safety of nonmyeloablative conditioning and hematopoietic cell transplantation&#xD;
      (HCT) from human leukocyte antigen (HLA)-haploidentical related donors for patients with&#xD;
      nonmalignant inherited disorders who do not have an HLA-matched related or unrelated donor.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine whether nonmyeloablative conditioning and HCT from an HLA-haploidentical related&#xD;
      donor graft can establish mixed chimerism (&gt; 5% cluster of differentiation [CD]3+ donor&#xD;
      T-cell chimerism) in patients with nonmalignant inherited disorders.&#xD;
&#xD;
      II. Transplant related mortality at day 100.&#xD;
&#xD;
      III. Incidence and severity of graft-versus-host disease (GHVD).&#xD;
&#xD;
      IV. Immune reconstitution.&#xD;
&#xD;
      V. Infections during the first 200 days after HCT.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously&#xD;
      (IV) over 1 hour on days -6 to -2; cyclophosphamide IV over 1 hour on days -6 and -5; and&#xD;
      undergo total body irradiation on day -1.&#xD;
&#xD;
      TRANSPLANTATION: Patients undergo allogeneic bone marrow transplant on day 0.&#xD;
&#xD;
      POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on days 3&#xD;
      and 4, and mycophenolate mofetil orally (PO) every 8 hours on days 5-30 then twice daily&#xD;
      (BID) to day 40, and then if there is no evidence of active GVHD and donor engraftment is &gt;&#xD;
      95% (or by principal investigator [PI] approval) taper until approximately day 96, or faster&#xD;
      at discretion of PI. Patients also receive tacrolimus IV continuously over 22-24 hours&#xD;
      starting on day 5 post-transplant and continue on tacrolimus through day 100 followed by a&#xD;
      taper to approximately day 180 if there is no evidence of GVHD and their graft is doing well.&#xD;
      Patients may convert to oral tacrolimus given BID or three times daily (TID) when the patient&#xD;
      is able to take medications orally and has a therapeutic drug level. In addition, patients&#xD;
      will receive sirolimus PO beginning on day 5 through day 180 followed by a taper to&#xD;
      approximately day 210 if there is no evidence of GVHD and their graft is doing well.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 6, 12, 18, and 24 months,&#xD;
      and then annually for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">May 24, 2006</start_date>
  <completion_date type="Actual">May 25, 2019</completion_date>
  <primary_completion_date type="Actual">August 17, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft Rejection</measure>
    <time_frame>Day 84</time_frame>
    <description>Number of patients with graft rejection (CD3 donor chimerisms &lt;5%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft Failure</measure>
    <time_frame>Day 84</time_frame>
    <description>Number of patients with graft failure (grade IV thrombocytopenia and neutropenia after day 21 that lasts &gt; 2 weeks andn is refractory to growth factor support).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Achieve Greater Than 5% Donor T-cell Chimerism</measure>
    <time_frame>By day 84</time_frame>
    <description>Number of patients who achieve greater than 5% donor T-cell (CD3+) chimerisms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Transplant Related Mortality</measure>
    <time_frame>Day 100 post transplant</time_frame>
    <description>The number of patients with transplant related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade I/II Acute Graft Versus Host Disease (GVHD)</measure>
    <time_frame>Day 100 post transplant</time_frame>
    <description>Number of patients diagnosed with overall GI/G2 acute GVHD by Day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade III/IV Acute Graft Versus Host Disease (GVHD)</measure>
    <time_frame>Day 100 post transplant</time_frame>
    <description>Number of patients diagnosed with overall GIII/IV acute GVHD by Day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic GVHD</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Number of patients diagnosed with chronic GVHD by 1 year post transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Number of patients with normal range CD3 @ 1 year post transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Infections</measure>
    <time_frame>Through day 200 after HCT</time_frame>
    <description>Number of patients with clinically significant infections requiring treatment within 200 days after HCT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Immunodeficiency Syndrome</condition>
  <condition>Severe Aplastic Anemia</condition>
  <condition>Genetic Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo allogeneic bone marrow transplantation</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic bone marrow transplantation</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>Non-myeloablative allogeneic transplant</other_name>
    <other_name>Nonmyeloablative Stem Cell Transplantation</other_name>
    <other_name>NST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>AY 22989</other_name>
    <other_name>RAPA</other_name>
    <other_name>Rapamune</other_name>
    <other_name>Rapamycin</other_name>
    <other_name>SILA 9268A</other_name>
    <other_name>WY-090217</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo total-body irradiation</description>
    <arm_group_label>Treatment (chemo, total-body irradiation, transplant)</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary immunodeficiency disorder or other nonmalignant inherited disease (except&#xD;
             Fanconi anemia) treatable by allogeneic HCT&#xD;
&#xD;
          -  Patients with pre-existing medical conditions or other factors that renders them at&#xD;
             high risk for regimen related toxicity or ineligible for conventional myeloablative&#xD;
             HCT and who do not have HLA-matched related or unrelated donors&#xD;
&#xD;
          -  Patients with a related donor who is identical for one HLA haplotype&#xD;
&#xD;
          -  Acquired aplastic anemia: severe aplastic anemia (SAA) is defined as follows:&#xD;
&#xD;
               -  Bone marrow cellularity &lt; 25%, or marrow cellularity &lt; 50% but with &lt; 30%&#xD;
                  residual hematopoietic cells&#xD;
&#xD;
               -  Two out of three of the following (in peripheral blood): neutrophils &lt; 0.5 x&#xD;
                  10^9/L; platelets &lt; 20 x 10^9/L; reticulocytes &lt; 20 x 10^9/L&#xD;
&#xD;
               -  SAA diagnostic criteria may be applied to assessment at initial diagnosis or&#xD;
                  follow-up assessments&#xD;
&#xD;
          -  DONOR: Related donors who are identical for one HLA haplotype&#xD;
&#xD;
          -  DONOR: Bone marrow will be the only allowed stem cell source&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fanconi anemia&#xD;
&#xD;
          -  Suitably HLA-matched related or unrelated donors&#xD;
&#xD;
          -  Patients with metabolic storage diseases who have severe central nervous system (CNS)&#xD;
             involvement of disease, defined as intelligence quotient (IQ) score &lt; 70&#xD;
&#xD;
          -  Cardiac ejection fraction &lt; 30% (or, if unable to obtain ejection fraction, shortening&#xD;
             fraction &lt; 26%) on multiple-gated acquisition (MUGA) scan or cardiac echocardiogram&#xD;
             (echo), symptomatic coronary artery disease, or other cardiac failure requiring&#xD;
             therapy; patients with a history of, or current cardiac disease should be evaluated&#xD;
             with appropriate cardiac studies and/or cardiology consult; patients with a shortening&#xD;
             fraction of &lt; 26% must be seen by cardiology for approval&#xD;
&#xD;
          -  Poorly controlled hypertension despite anti-hypertensive medications&#xD;
&#xD;
          -  Patients with clinical or laboratory evidence of liver disease will need to be&#xD;
             evaluated for the cause of the liver disease, its clinical severity in terms of liver&#xD;
             function and the degree of portal hypertension; patients will be excluded if they are&#xD;
             found to have fulminant liver failure, cirrhosis of the liver with evidence of portal&#xD;
             hypertension, bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of&#xD;
             bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic&#xD;
             dysfunction evidenced by prolongation of the prothrombin time, ascites related to&#xD;
             portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic&#xD;
             viral hepatitis with total serum bilirubin &gt; 3 mg/dl, or symptomatic biliary disease&#xD;
&#xD;
          -  Positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Females who are pregnant (beta-human chorionic gonadotropin positive [beta-HCG+]) or&#xD;
             breast-feeding&#xD;
&#xD;
          -  Fertile men or women who are unwilling to use contraceptives during HCT and up to 12&#xD;
             months post-treatment&#xD;
&#xD;
          -  Patients with fungal pneumonia with radiological progression after receipt of&#xD;
             amphotericin formulation or mold-active azoles for greater than 1 month will not be&#xD;
             eligible for this protocol (either regimen A or B)&#xD;
&#xD;
          -  DONOR: Donor-recipient pairs in which the HLA-mismatch is only in the&#xD;
             host-versus-graft (HVG) direction; patients are homozygous and donor is heterozygous&#xD;
&#xD;
          -  DONOR: Donors who are not expected to meet the minimum target dose of marrow cells (1&#xD;
             x 10^8 nucleated cells/kg recipient ideal body weight)&#xD;
&#xD;
          -  DONOR: HIV-positive donors&#xD;
&#xD;
          -  DONOR: A positive anti-donor cytotoxic cross match is absolute donor exclusion&#xD;
&#xD;
          -  DONOR: &lt; 6 months old and &gt; 75 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kanwaldeep Mallhi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital at TriStar Centennial</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 28, 2006</study_first_submitted>
  <study_first_submitted_qc>July 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2006</study_first_posted>
  <results_first_submitted>January 6, 2021</results_first_submitted>
  <results_first_submitted_qc>January 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 26, 2021</results_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Kanwaldeep K Mallhi</investigator_full_name>
    <investigator_title>Assistant Professor, Clinical Research Division, Fred Hutch</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT00358657/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
          <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
          <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.7" lower_limit="0.62" upper_limit="21.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Graft Rejection</title>
        <description>Number of patients with graft rejection (CD3 donor chimerisms &lt;5%).</description>
        <time_frame>Day 84</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
            <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Rejection</title>
          <description>Number of patients with graft rejection (CD3 donor chimerisms &lt;5%).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Graft Failure</title>
        <description>Number of patients with graft failure (grade IV thrombocytopenia and neutropenia after day 21 that lasts &gt; 2 weeks andn is refractory to growth factor support).</description>
        <time_frame>Day 84</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
            <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Failure</title>
          <description>Number of patients with graft failure (grade IV thrombocytopenia and neutropenia after day 21 that lasts &gt; 2 weeks andn is refractory to growth factor support).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Achieve Greater Than 5% Donor T-cell Chimerism</title>
        <description>Number of patients who achieve greater than 5% donor T-cell (CD3+) chimerisms</description>
        <time_frame>By day 84</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
            <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Achieve Greater Than 5% Donor T-cell Chimerism</title>
          <description>Number of patients who achieve greater than 5% donor T-cell (CD3+) chimerisms</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Transplant Related Mortality</title>
        <description>The number of patients with transplant related mortality</description>
        <time_frame>Day 100 post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
            <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Transplant Related Mortality</title>
          <description>The number of patients with transplant related mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade I/II Acute Graft Versus Host Disease (GVHD)</title>
        <description>Number of patients diagnosed with overall GI/G2 acute GVHD by Day 100</description>
        <time_frame>Day 100 post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
            <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade I/II Acute Graft Versus Host Disease (GVHD)</title>
          <description>Number of patients diagnosed with overall GI/G2 acute GVHD by Day 100</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade III/IV Acute Graft Versus Host Disease (GVHD)</title>
        <description>Number of patients diagnosed with overall GIII/IV acute GVHD by Day 100</description>
        <time_frame>Day 100 post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
            <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade III/IV Acute Graft Versus Host Disease (GVHD)</title>
          <description>Number of patients diagnosed with overall GIII/IV acute GVHD by Day 100</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Chronic GVHD</title>
        <description>Number of patients diagnosed with chronic GVHD by 1 year post transplant</description>
        <time_frame>1 year post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
            <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Chronic GVHD</title>
          <description>Number of patients diagnosed with chronic GVHD by 1 year post transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution</title>
        <description>Number of patients with normal range CD3 @ 1 year post transplant</description>
        <time_frame>1 year post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
            <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution</title>
          <description>Number of patients with normal range CD3 @ 1 year post transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Infections</title>
        <description>Number of patients with clinically significant infections requiring treatment within 200 days after HCT</description>
        <time_frame>Through day 200 after HCT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
            <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Infections</title>
          <description>Number of patients with clinically significant infections requiring treatment within 200 days after HCT</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 200 post initiation of conditioning therapy</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Chemo, Total-body Irradiation, Transplant)</title>
          <description>See Detailed Description&#xD;
Allogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Cyclophosphamide: Given IV&#xD;
Fludarabine Phosphate: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Mycophenolate Mofetil: Given PO&#xD;
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic bone marrow transplantation&#xD;
Sirolimus: Given PO&#xD;
Tacrolimus: Given IV or PO&#xD;
Total-Body Irradiation: Undergo total-body irradiation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis with shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia requiring mechanical ventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hemolytic uremic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pancreatisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kanwaldeep Mallhi</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-2014</phone>
      <email>kmallhi@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

